Recently, Gpx3 has been identified as a novel regulator of insulin receptor expression, and Gpx3 dysregulation would impact insulin receptor and lead to insulin resistance, a not uncommon feature in PAH patients (Pugh et al., 2013; Bradley and Bradley, 2014; Hauffe et al., 2020). Here, INSR is linked to pulmonary arterial hypertension.